Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 1236Neoplasms 1040Carcinoma, Non-Small-Cell Lung 861Prostatic Neoplasms 692Colorectal Neoplasms 614Lung Neoplasms 578Neoplasm Metastasis 439Multiple Myeloma 425Leukemia, Myeloid, Acute 401Pancreatic Neoplasms 376Ovarian Neoplasms 364Melanoma 320Carcinoma, Hepatocellular 288Recurrence 276Squamous Cell Carcinoma of Head and Neck 275Brain Neoplasms 266Glioblastoma 247Head and Neck Neoplasms 244Stomach Neoplasms 239Carcinoma, Renal Cell 228Precursor Cell Lymphoblastic Leukemia-Lymphoma 227Lymphoma 225Triple Negative Breast Neoplasms 219Hematologic Neoplasms 209Endometrial Neoplasms 209Urinary Bladder Neoplasms 202Lymphoma, Non-Hodgkin 197Uterine Cervical Neoplasms 194Sarcoma 190Glioma 190

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Jaw Neoplasms × 90 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡